Author Correction: PD-1 blockade in subprimed CD8 cells induces dysfunctional PD-1⁺CD38^hi cells and anti-PD-1 resistance

Affiliations

• ¹ Georgia Cancer Center, Augusta University, Augusta, GA, USA.
• ² The Loop Immuno-Oncology Laboratory, Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, DC, USA.
• ³ Therapeutic Discovery, MD Anderson Cancer Center, Houston, TX, USA.
• ⁴ Five Prime Therapeutics Inc., South San Francisco, CA, USA.
• ⁵ Department of Medicine, Massachusetts General Hospital Cancer Center, Boston, MA, USA.
• ⁶ Broad Institute of Massachusetts Institute of Technology and Harvard, Cambridge, MA, USA.
• ⁷ Department of Surgical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
• ⁸ Department of Surgery, Massachusetts General Hospital, Boston, MA, USA.
• ⁹ Department of Pathology, Massachusetts General Hospital, Boston, MA, USA.
• ¹⁰ MedImmune LLC, Gaithersburg, MD, USA.
• ¹¹ Department of Biostatistics, Bioinformatics & Biomathematics, Georgetown University, Washington, DC, USA.
• ¹² Memorial Sloan Kettering Cancer Center, New York, NY, USA.
• ¹³ Weill Cornell Medical and Graduate Schools, New York, NY, USA.
• ¹⁴ Incyte Inc., Wilmington, DE, USA.
• ¹⁵ A2 Biotherapeutics, Agoura Hills, CA, USA.
• ¹⁶ Georgia Cancer Center, Augusta University, Augusta, GA, USA. [email protected].
• ¹⁷ The Loop Immuno-Oncology Laboratory, Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, DC, USA. [email protected].